12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Company News  |  Deals

Antex, SmithKline deal

The companies restructured their 1996 agreement to develop infectious disease vaccines, dissolving their joint venture, MicroCarb Human Vaccines (see BioCentury, May 13, 1996). Under the agreement, SmithKline had an exclusive worldwide license to any human infectious disease...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >